Healthcare / Drug Manufacturers - Specialty & GenericTaipei Exchange
$119.50
-2.50 (-2.05%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-76.5M · quality 63.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$8.0B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-3.3%
↓Gross Margin
77.7%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+51.0%
FCF CAGR
—
FCF margin
-6316.7%
FCF / Net income
2.18x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.8M · net income $-79.7M · FCF $-173.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.8M | $2.8M | $5.8M | $469.3M | $800000.00 |
| Net Income | $-79.7M | $-79.7M | $18.2M | $382.6M | $-19.9M |
| EBITDA | $-74.0M | $-74.0M | $41.0M | $394.5M | $-29.3M |
| EPS | — | — | 0.27 | 6.71 | -0.35 |
| Gross Margin | 77.7% | 77.7% | 65.2% | 100.0% | — |
| Operating Margin | -6095.1% | -6095.1% | -1168.0% | 82.2% | -5815.9% |
| Net Margin | -2894.4% | -2894.4% | 312.4% | 81.5% | -2483.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Current Ratio | 25.01 | 25.01 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-173.9M | $-173.9M | $-76.5M | $397.2M | $-34.1M |
| Returns | |||||
| ROE | -3.3% | -3.3% | 0.7% | 42.6% | -3.9% |
| Valuation | |||||
| P/E | — | — | 490.74 | 30.48 | — |
| EV/EBITDA | — | — | 183.40 | 27.70 | — |
| P/B | 3.32 | 3.32 | 3.58 | 13.00 | 12.63 |
| Growth & Yield | |||||
| Revenue Growth | -52.7% | -52.7% | -98.8% | 58559.0% | — |
| EPS Growth | — | — | -96.0% | 2017.1% | — |
| Dividend Yield | 0.2% | 0.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-12.3%
Start / end P/E
n/dx → n/dx
EPS bridge
0.27 → n/d
Residual
-12.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.